Neuropathic pain is known to negatively impact all aspects of function and substantially reduce health-related quality of life. ” This type of pain is estimated to affect millions of people worldwide. Neuropathic pain has recently been redefined from the International Association for the Study of Pain (IASP) 1994 definition to “pain arising as a direct consequence of a lesion or disease affecting the somatosensory system. New alternatives for managing neuropathic pain, such as the high-concentration capsaicin patch, will enlarge the treatment armamentarium and potentially impact therapeutic guidelines.Īnalgesics, Guidelines, Neuropathic Pain, Peripheral Neuropathic Pain, Recommendations, Treatment Introduction
#Phantom pain management alogothim trial#
As the evidence base expands, the addition of new comparative trial data will further refine the development of new guidance for clinical management of neuropathic pain. Still, significant knowledge gaps in the treatment of neuropathic pain conditions have hampered the development of algorithms and multimodal approaches. The analgesics common to these guidelines are topical lidocaine, secondary amine tricyclic antidepressants, serotonin and norepinephrine dual reuptake inhibitors, calcium channel α 2-δ ligands, tramadol, and opioid antagonists. Worldwide, five sets of treatment recommendations offer insight into managing neuropathic pain, including two European guidelines, one Canadian, one Latin American, and another constructed under the auspices of the International Association for the Study of Pain (IASP).
Neuropathic pain often imposes a substantial and unrelenting burden on those individuals who have it single-agent analgesics typically only reduce pain at best.